Stockscreener 앱 받기
3.993
3.15%
-0.127
전일 마감가:
$4.12
열려 있는:
$4.17
하루 거래량:
261.91K
Relative Volume:
0.79
시가총액:
$177.87M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-16.87%
1개월 성능:
-23.27%
6개월 성능:
-70.88%
1년 성능:
+0.00%
1일 변동 폭
$3.96
$4.17
1주일 범위
$3.94
$4.85
52주 변동 폭
$3.94
$30.60
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| KYTX | 4.00 | 177.87M | 0 | 0 | 0 | 0.00 |
| VRTX | 449.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.85 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.02 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna stock plunges 28% amid data update on lead drug - MSN
H.C. Wainwright cuts Kyverna stock price target by 14%, keeps Neutral stance - Investing.com
Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright - MarketBeat
Kyverna stock maintains Neutral rating as analyst revises outlook amid higher costs - Investing.com UK
What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings? - Defense World
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop - Yahoo Finance
Wells Fargo & Company Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $24.00 - Defense World
Kyverna's CAR T-Cell Therapy Shows Promising Results in Lupus Nephritis Treatment | KYTX Stock News - StockTitan
Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - StreetInsider.com
(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat
(KYTX) Trading Report - Stock Traders Daily
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors | KYTX Stock News - StockTitan
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey
(KYTX) Technical Data - Stock Traders Daily
500: Something went wrong - Investing.com
JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK
7 Best Nano Cap Stocks To Invest In - Insider Monkey
The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News
Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com
Down rounds don’t aid post-IPO performance - BioCentury
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa
Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex
Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN
MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics Inc (KYTX) 재무 분석
Kyverna Therapeutics Inc (KYTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Kyverna Therapeutics Inc 주식 (KYTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
| Vida Ventures, LLC | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
253,136 |
5,568,992 |
252,553 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
3,163,868 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
| Northpond Ventures III GP, LLC | Former 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
450,000 |
1.80%
0.42%
자본화:
|
볼륨(24시간):